Kaleido Biosciences Inc., of Lexington, Mass., priced its IPO of 5 million shares at $15, $5 below the low end of its intended range, to raise $75 million. Kaleido granted underwriters a 30-day option to purchase up to 750,000 additional shares, potentially adding $11.25 million.